• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症免疫疗法：重新编程固有和适应性免疫系统的细胞。

Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems.

机构信息

Department of Microbiology and Immunology; Virginia Commonwealth University Massey Cancer Center; Richmond, VA USA.

出版信息

Oncoimmunology. 2012 Mar 1;1(2):201-204. doi: 10.4161/onci.1.2.18113.

DOI:10.4161/onci.1.2.18113
PMID:22720242
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3377002/
Abstract

Cancers utilize multiple mechanisms to overcome immune responses. Emerging evidence suggest that immunotherapy of cancer should focus on inducing and re-programming cells of the innate and adaptive immune systems rather than focusing solely on T cells. Recently, we have shown that such a multifaceted approach can improve immunotherapy of breast cancer.

摘要

癌症利用多种机制来克服免疫反应。新出现的证据表明，癌症的免疫疗法应该侧重于诱导和重新编程先天和适应性免疫系统的细胞，而不仅仅是集中于 T 细胞。最近，我们已经表明，这种多方面的方法可以改善乳腺癌的免疫疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce86/3377002/cd8e3796317f/onci-1-201-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce86/3377002/cd8e3796317f/onci-1-201-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce86/3377002/cd8e3796317f/onci-1-201-g1.jpg

相似文献

1
Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems.癌症免疫疗法：重新编程固有和适应性免疫系统的细胞。
Oncoimmunology. 2012 Mar 1;1(2):201-204. doi: 10.4161/onci.1.2.18113.
2
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.作为乳腺癌免疫治疗靶点的先天性和适应性浸润免疫系统。
Endocr Relat Cancer. 2017 Apr;24(4):R123-R144. doi: 10.1530/ERC-16-0404. Epub 2017 Feb 13.
3
Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.癌症与先天免疫系统的相互作用：癌症免疫治疗的转化潜力。
J Immunother. 2012 May;35(4):299-308. doi: 10.1097/CJI.0b013e3182518e83.
4
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.头颈部癌的免疫治疗：超越检查点阻断。
J Dent Res. 2019 Sep;98(10):1073-1080. doi: 10.1177/0022034519864112. Epub 2019 Jul 24.
5
Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy.使用选择性I型蛋白激酶A（PKAI）抑制剂靶向肿瘤相关免疫抑制可能会增强癌症免疫疗法。
Med Hypotheses. 2016 Jan;86:56-9. doi: 10.1016/j.mehy.2015.11.031. Epub 2015 Dec 11.
6
Cooperativity of adaptive and innate immunity: implications for cancer therapy.适应性免疫和固有免疫的协同作用：对癌症治疗的启示。
Cancer Immunol Immunother. 2011 Aug;60(8):1061-74. doi: 10.1007/s00262-011-1053-z. Epub 2011 Jun 9.
7
Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.科利免疫疗法的复兴：先天免疫作为启动适应性免疫攻击癌细胞的联系。
Semin Oncol. 2019 Aug-Oct;46(4-5):385-392. doi: 10.1053/j.seminoncol.2019.10.004. Epub 2019 Nov 6.
8
Immunotherapy of cancer: reprogramming tumor-immune crosstalk.癌症免疫疗法：重编程肿瘤与免疫的相互作用
Clin Dev Immunol. 2012;2012:760965. doi: 10.1155/2012/760965. Epub 2012 Oct 11.
9
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.固有效应细胞在控制癌症进展中的正负作用。
Front Immunol. 2018 Sep 21;9:1990. doi: 10.3389/fimmu.2018.01990. eCollection 2018.
10
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.激活 cGAS-STING 通路以获得癌症免疫治疗的最佳效果。
J Hematol Oncol. 2019 Apr 1;12(1):35. doi: 10.1186/s13045-019-0721-x.

引用本文的文献

1
Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms.硼衍生物通过不同机制抑制乳腺癌细胞增殖并影响体外肿瘤特异性T细胞活性。
Biol Trace Elem Res. 2023 Dec;201(12):5692-5707. doi: 10.1007/s12011-023-03632-0. Epub 2023 Mar 20.
2
The association between gene rs3116496 polymorphism and breast cancer risk in Chinese women.基因 rs3116496 多态性与中国女性乳腺癌风险的关联。
Biosci Rep. 2017 Dec 12;37(6). doi: 10.1042/BSR20170884. Print 2017 Dec 22.
3
A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.

本文引用的文献

1
The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment.NKT 细胞辅助和全反式维甲酸治疗恢复髓源性抑制细胞的功能抗原呈递细胞。
Int J Cancer. 2012 Aug 1;131(3):741-51. doi: 10.1002/ijc.26411. Epub 2011 Oct 20.
2
Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.活化的 NKT 细胞和 NK 细胞使 T 细胞抵抗髓源抑制细胞，并在 FVBN202 转基因小鼠中导致有效的过继细胞治疗乳腺癌。
J Immunol. 2011 Jul 15;187(2):708-17. doi: 10.4049/jimmunol.1100502. Epub 2011 Jun 13.
3
对涉及操纵不变自然杀伤T细胞作为未来癌症治疗中一种有前景方法的临床试验的简要综述。
Cent Eur J Immunol. 2017;42(2):181-195. doi: 10.5114/ceji.2017.69361. Epub 2017 Aug 8.
4
HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma.髓系细胞上的HLA-DR表达是高危神经母细胞瘤患者的一个潜在预后因素。
Oncoimmunology. 2013 Oct 1;2(10):e26616. doi: 10.4161/onci.26616. Epub 2013 Oct 10.
5
Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?药物受体酪氨酸激酶抑制剂能否使预后不良的乳腺癌肿瘤对免疫治疗敏感？
Front Oncol. 2013 Feb 13;3:23. doi: 10.3389/fonc.2013.00023. eCollection 2013.
6
T cell coinhibition and immunotherapy in human breast cancer.人类乳腺癌中的T细胞共抑制与免疫治疗
Discov Med. 2012 Oct;14(77):229-36.
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
在胰腺癌、食管癌和胃癌中，髓源性抑制细胞的升高是一个独立的预后因素，并且与 Th2 细胞因子白细胞介素-13 的显著升高相关。
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30. doi: 10.1007/s00262-011-1028-0. Epub 2011 Jun 5.
4
Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients.心理压力与乳腺癌患者骨髓来源抑制性细胞水平的改变有关。
Cell Immunol. 2011;270(1):80-7. doi: 10.1016/j.cellimm.2011.04.003. Epub 2011 Apr 23.
5
Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells.苔藓抑素 1 是一种天然存在的抗肿瘤药物，作为 Toll 样受体 4（TLR-4）配体，在树突状细胞中诱导独特的细胞因子和趋化因子。
J Biol Chem. 2011 Jan 7;286(1):24-34. doi: 10.1074/jbc.M110.135921. Epub 2010 Oct 29.
6
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.黑素瘤患者中不成熟的免疫抑制性 CD14+HLA-DR-/low 细胞是 Stat3hi，并且过度表达 CD80、CD83 和 DC-sign。
Cancer Res. 2010 Jun 1;70(11):4335-45. doi: 10.1158/0008-5472.CAN-09-3767. Epub 2010 May 18.
7
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.粒细胞-巨噬细胞集落刺激因子（GM-CSF）是主要的乳腺癌来源的可溶性因子之一，可诱导 CD11b-Gr1-骨髓祖细胞向髓源性抑制细胞分化。
Breast Cancer Res Treat. 2010 Aug;123(1):39-49. doi: 10.1007/s10549-009-0622-8. Epub 2009 Nov 8.
8
Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.免疫抑制性髓源性抑制细胞可在活化的自然杀伤T细胞的帮助下转化为具有免疫原性的抗原呈递细胞：一种替代性的基于细胞的抗肿瘤疫苗。
J Immunol. 2009 Feb 15;182(4):1818-28. doi: 10.4049/jimmunol.0802430.
9
IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis.白细胞介素-2受体γ链细胞因子对人类CD8⁺CD127⁺和CD8⁺CD127⁻ T细胞的增殖及凋亡易感性具有不同的调节作用。
Int Immunol. 2009 Jan;21(1):29-42. doi: 10.1093/intimm/dxn120. Epub 2008 Nov 14.
10
Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?癌症免疫治疗中的记忆性T细胞：哪种CD8 T细胞群体对肿瘤提供最佳保护？
Tissue Antigens. 2008 Sep;72(3):187-94. doi: 10.1111/j.1399-0039.2008.01088.x. Epub 2008 Jul 9.